Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Melanoma 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Glioma 1Ependymoma 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Gemcitabine 11Cisplatin 8pembrolizumab 2Oxaliplatin 2Nivolumab 2Docetaxel 2Capecitabine 2trametinib 1titanium silicide 1telotristat ethyl 1sovateltide 1niraparib 1milademetan 1folfirinox 1dostarlimab 1devimistat 1cytokine inducible SH2-containing protein 1brigimadlin 1bintrafusp alfa protein, human 1becatecarin 1adagrasib 1Sorafenib 1S 1 (combination) 1Pancreaticojejunostomy 1NUC-1031 1Leucovorin 1Hydroxychloroquine 1Fluorouracil 1Cetuximab 1Catheter Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Biliary Tract Neoplasms × AZD 6244 × Clear all
NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

AstraZeneca

Phase 1 Terminated
6 enrolled 6 charts
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡